A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.
Breast Cancer
DRUG: D-0502|DRUG: Fulvestrant
Progression free survival (PFS) assessed by Independent Review Committee (IRC), From enrollment to the end of treatment, up to 2 years
Progression free survival (PFS) -assessed by investigators, From enrollment to the end of treatment, up to 2 years|Objective response rate (ORR) -assessed by IRC and investigators, From enrollment to the end of treatment, up to 2 years|Clinical benefit rate (CBR) -assessed by IRC and investigators, From enrollment to the end of treatment, up to 2 years|Disease control rate (DCR)-assessed by IRC and investigators, From enrollment to the end of treatment, up to 2 years|Clearance (Cl) of D-0502, on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 (each cycle is 28 days)|Overall Survival (OS), From end of treatment to end of study, about 2 years|Number of participants with adverse events/serious adverse events and abnormal laboratory test results, From enrollment to 30 days after last dose|Volume of distribution (Vd) of D-0502, on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 (each cycle is 28 days)
This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.